tiprankstipranks
US Stem Cell Inc (USRM)
OTHER OTC:USRM

US Stem Cell (USRM) Stock Price & Analysis

26 Followers

USRM Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range― - ―
Previous Close$0.01
Volume2.00
Average Volume (3M)N/A
Market Cap
$642.00
Enterprise Value$8.94M
Total Cash (Recent Filing)$5.13K
Total Debt (Recent Filing)$8.95M
Price to Earnings (P/E)-2.0
Beta-24.08
Aug 07, 2019
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding641,507,317
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.39
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)0.01
Price to Cash Flow (P/CF)-17.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue134.39
Enterprise Value/Gross Profit153.43
Enterprise Value/Ebitda-4.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

12.50%0.00%0.00%87.50%
12.50%
Insiders
0.00%
Mutual Funds
0.00% Other Institutional Investors
87.50% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

USRM FAQ

What was US Stem Cell Inc’s price range in the past 12 months?
Currently, no data Available
What is US Stem Cell Inc’s market cap?
Currently, no data Available
When is US Stem Cell Inc’s upcoming earnings report date?
US Stem Cell Inc’s upcoming earnings report date is Aug 07, 2019 which is 1695 days ago.
    How were US Stem Cell Inc’s earnings last quarter?
    US Stem Cell Inc released its earnings results on May 07, 2019. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.002.
      Is US Stem Cell Inc overvalued?
      According to Wall Street analysts US Stem Cell Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does US Stem Cell Inc pay dividends?
        US Stem Cell Inc does not currently pay dividends.
        What is US Stem Cell Inc’s EPS estimate?
        US Stem Cell Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does US Stem Cell Inc have?
        US Stem Cell Inc has 641,507,300 shares outstanding.
          What happened to US Stem Cell Inc’s price movement after its last earnings report?
          US Stem Cell Inc reported an EPS of -$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
            Which hedge fund is a major shareholder of US Stem Cell Inc?
            Currently, no hedge funds are holding shares in USRM
            ---

            US Stem Cell Stock Smart Score

            N/A
            Not Ranked
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Company Description

            US Stem Cell Inc

            U.S. Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product MyoCell, deals with the clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company was founded by Howard J. Leonhardt and Robert D. Lashinski on August 12, 1999 and is headquartered in Sunrise, FL.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Onconova Therapeutics
            BioSig Technologies
            Viveve Medical
            vTv Therapeutics
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis